View Post

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

In Clinical Trials by Barbara Jacoby

From: scnow.com Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC). Approximately 20% of patients with TNBC have tumors that highly …

View Post

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Intensity Therapeutics Inc From: globenewswire.com Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed …

View Post

Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy

In In The News by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on …

View Post

Gold nanoparticle delivery of microRNA impairs metastasis in triple-negative breast cancer

In In The News by Barbara Jacoby

By: Weill Cornell Medical College From: medicalxpress.com Weill Cornell Medicine researchers have shown that giving mice with triple-negative breast cancer therapeutic microRNA (miRNA) in a protective gold nanoparticle results in significantly less spreading of cancer to the lung. Triple-negative breast cancer is a highly aggressive, difficult-to-treat form of the disease, with a high rate of metastatic recurrence. miR-708 is a …

View Post

Roche’s ipatasertib combo shows early promise in triple-negative breast cancer

In Clinical Trials by Barbara Jacoby

By: Anna Smith From: pharmatimes.com Roche has announced results from a Phase Ib trial assessing its AKT-inhibitor ipatasertib, Tecentriq (atezolizumab) and chemotherapy in triple-negative breast cancer (TNBC), showing a 73% overall response rate irrespective of PD-L1 status. Out of the first 26 subjects in the study, 19 had confirmed responses.The trial consisted of two arms; ipatasertib in combination with Tecentriq and …

View Post

Targeting triple-negative breast cancer with new drug design

In In The News by Barbara Jacoby

By: Laura Castañón, Northeastern University From: medicalxpress.com The type of breast cancer most likely to affect young people and African Americans is also one of the most aggressive and difficult to treat. Triple-negative breast cancer, which represents about 20 percent of all breast cancer cases, is named for its lack of three common hormone receptors. Since targeted breast cancer treatments …

View Post

Public domain antibiotic found highly effective against triple-negative breast cancer

In In The News by Barbara Jacoby

Source: University of Geneva From: medicalxpress.com Of the three major subtypes of breast cancer, triple negative is the most lethal. Half of all breast cancer deaths are attributed to it, whereas it accounts for only about 15 percent of incidences of breast cancer. And unlike other breast cancers, it is resistant to most existing therapies. By studying the properties of …

View Post

Estrogen May Trigger Brain Metastasis in Triple-negative Breast Cancer, Study Shows

In In The News by Barbara Jacoby

By: Ana Pena From: breastcancer-news.com Estradiol, a type of estrogen and the major female hormone, may drive the spread of cancer to the brain in women with triple-negative breast cancer (TNBC), a study in mice and human cells reports. Researchers identified a chain of molecular events triggered by estradiol that appears to be behind tumor cells’ ability to form brain …

View Post

Triple-negative breast cancer: Recurrence and survival rates

In In The News by Barbara Jacoby

By: Jenna Fletcher From: medicalnewstoday.com Triple-negative breast cancer is an aggressive form of the disease. To understand it, a person should know about the other types of breast cancer. Some breast cancers have receptor cells that respond to hormones. There are three main types of receptors: estrogen receptor progesterone receptor human epidermal growth factor receptor 2 Doctors diagnose breast cancer …

View Post

Antipsychotic Drug Blocks Triple-Negative Breast Cancer Growth

In Clinical Trials by Barbara Jacoby

From: genengnews.com The results of studies by a team of scientists in the U.K. and Spain suggest that the commonly used antipsychotic drug Pimozide could offer a new treatment approach to the most hard to treat form of breast cancer, and potentially for lung cancer. The research, headed by Mohamed El-Tanani, Ph.D., professor of molecular pathology and cancer therapeutics at …